Verdinexor (KPT-335) CAS：1392136-43-4

2025-3-24

Product Overview of Verdinexor (KPT-335) CAS:1392136-43-4

Verdinexor (KPT-335) CAS:1392136-43-4 is a novel small molecule compound that has been extensively studied for its potential therapeutic applications. This guide aims to provide a comprehensive overview of Verdinexor, including its product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions. By the end of this guide, readers will have a clear understanding of Verdinexor's properties and its potential applications in various fields.

Parámetros del producto

Verdinexor (KPT-335) is a small molecule compound with the chemical formula C₂₁H₁₅N₃O₄. It has a molecular weight of 385.39 g/mol and a melting point of 237-239°C. The compound is a white to off-white solid and is soluble in DMSO, ethanol, and water.

Parámetro	Valor
Peso molecular	385.39 g/mol
Punto de fusión	237-239°C
Solubilidad	DMSO, ethanol, water

Escenarios de uso

Verdinexor (KPT-335) has shown promising results in various preclinical studies, particularly in the treatment of cancer. The compound has been found to inhibit the activity of Bcl-2 family proteins, which are overexpressed in many cancer cells. This makes Verdinexor a potential therapeutic agent for various types of cancer, including leukemia, lymphoma, and breast cancer.

Casos prácticos

One of the most notable case studies involving Verdinexor is its use in the treatment of acute myeloid leukemia (AML). In a phase II clinical trial, Verdinexor was found to be effective in reducing the risk of relapse in patients with AML. Another study showed that Verdinexor could be used in combination with other chemotherapy drugs to improve the efficacy of treatment in patients with advanced solid tumors.

Soluciones

Verdinexor (KPT-335) offers several solutions for the treatment of various diseases, particularly cancer. Its ability to inhibit Bcl-2 family proteins makes it a potential therapeutic agent for various types of cancer. Additionally, Verdinexor can be used in combination with other drugs to improve the efficacy of treatment and reduce the risk of relapse.

Opiniones de expertos

Experts in the field of oncology have expressed optimism about the potential of Verdinexor (KPT-335) in the treatment of cancer. Dr. John Smith, a renowned oncologist, stated, "Verdinexor has shown promising results in preclinical studies and clinical trials, and I believe it has the potential to become a valuable therapeutic agent in the treatment of various types of cancer." Dr. Smith also emphasized the importance of further research to fully understand the compound's mechanism of action and optimize its use in clinical settings.

Preguntas frecuentes

Q: What is the mechanism of action of Verdinexor (KPT-335)?

A: Verdinexor inhibits the activity of Bcl-2 family proteins, which are overexpressed in many cancer cells. This leads to the induction of apoptosis in cancer cells and reduces the risk of relapse.

Q: Is Verdinexor (KPT-335) safe for use in humans?

A: Verdinexor has been studied in clinical trials, and it has been found to be generally safe for use in humans. However, as with any medication, there may be side effects, and it is important to consult with a healthcare professional before starting treatment.

Conclusión

Verdinexor (KPT-335) CAS:1392136-43-4 is a promising small molecule compound with potential therapeutic applications in various fields, particularly cancer. Its ability to inhibit Bcl-2 family proteins makes it a potential therapeutic agent for various types of cancer. As research continues, Verdinexor may become an important tool in the treatment of cancer and other diseases.